After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension

被引：0
|
作者：
Tamargo, Juan [1 ]
机构：
[1] Univ Complutense, Sch Med, Dept Pharmacol & Toxicol, Plaza Ramon y Cajal S-N, Madrid 28040, Spain
来源：
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY | 2024年 / 10卷 / 05期
关键词：
D O I：
10.1093/ehjcvp/pvae035
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：371 / 373
页数：3
相关论文
共 50 条
  • [31] Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats
    Hill, NS
    Warburton, RR
    Pietras, L
    Klinger, JR
    [J]. JOURNAL OF APPLIED PHYSIOLOGY, 1997, 83 (04) : 1209 - 1215
  • [32] Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
    Barst, Robyn J.
    Langleben, David
    Badesch, David
    Frost, Adaani
    Lawrence, E. Clinton
    Shapiro, Shelley
    Naeije, Robert
    Galie, Nazzareno
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (10) : 2049 - 2056
  • [33] Investigating the endothelin receptor antagonist aprocitentan in resistant hypertension: design and baseline characteristics of the PRECISION study
    Danaietash, P.
    Verweij, P.
    Wang, J.
    Dresser, G.
    Kantola, I.
    Lawrence, M. K.
    Narkiewicz, K.
    Schlaich, M.
    Bellet, M.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 2362 - 2362
  • [34] Long-term survival with end-stage idiopathic pulmonary arterial hypertension (EPAH): Impact of prostanoid and endothelin-receptor antagonist treatment after patients' listing for transplantation
    Daudet, M.
    Lehmkuhl, H. B.
    Mulahasanovic, S.
    Weng, Y.
    Grauban, O.
    Knosalla, C.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (02): : S117 - S117
  • [35] Switch of patients with pulmonary arterial hypertension after withdrawal of the endothelin receptor antagonist sitaxentan
    Pittrow, David
    Ghofrani, Ardeschir
    Rosenkranz, Stephan
    Gruenig, Ekkehard
    Huscher, Doerte
    Tiede, Henning
    Delcroix, Marion
    Staehler, Gerd
    Halank, Michael
    Held, Matthias
    Grohe, Christian
    Lange, Tobias J.
    Behr, Juergen
    Klose, Hans
    Wilkens, Heinrike
    Speich, Rudolph
    Kaehler, Christian M.
    Filusch, Arthur
    Germann, Martin
    Ewert, Ralf
    Seyfarth, Hans-Juergen
    Olsson, Karen M.
    Opitz, Christian F.
    Gaine, Sean P.
    Vizza, C. Dario
    Vonk-Noordegraaf, Anton
    Kaemmerer, Harald
    Gibbs, J. Simon R.
    Distler, Oliver
    Schweiger, Christian
    Hoeper, Marius M.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [36] Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases
    Marc Humbert
    Gérald Simonneau
    [J]. Nature Clinical Practice Rheumatology, 2005, 1 : 93 - 101
  • [37] Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases
    Humbert, M
    Simonneau, G
    [J]. NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2005, 1 (02): : 93 - 101
  • [38] Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
    Correale, Michele
    Ferraretti, Armando
    Monaco, Ilenia
    Grazioli, Davide
    Di Biase, Matteo
    Brunetti, Natale Daniele
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2018, 14 : 253 - 264
  • [39] Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension
    Annette S Droste
    David Rohde
    Mirko Voelkers
    Arthur Filusch
    Thomas Bruckner
    Mathias M Borst
    Hugo A Katus
    F Joachim Meyer
    [J]. Respiratory Research, 10
  • [40] Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis
    John Varga
    [J]. Current Rheumatology Reports, 2003, 5 (2) : 145 - 146
12345